While the lead vaccine candidate Advertisement02 is in stage II clinical testing currently, two additional preclinical programmes successfully have already been completed. Based on the promising preliminary results of the programme, GSK exercised its choice for the alternative vaccine candidates which triggered a EUR 2.5 million payment to AFFiRiS impotence . An additional EUR 1 million payment became thanks for the successful completion of testing of alternative vaccine formulations concurrently. AFFiRiS announced today the effective completion of preclinical work packages and related payments of EUR 3.5 million from GSK to AFFiRiS. The collaboration is founded on a license and option contract announced in October 2008.